Other CSGs are involved in angiogenesis, where the pathogenic mutations cause overactivity of the vascular endothelial growth factor (VEGF) and other hypoxia‐inducing factor (HIF) target genes, as in von Hippel–Lindau disease (VHL), causing an increased risk of vascular tumours such as renal cell carcinoma and cerebellar hemangioblastoma (Maher et al. Here, VEGFA is linked to vascular neoplasm.